Immune Checkpoint Inhibitors as Independent and Synergistic Drivers of SJS/TEN

JAMA Oncol. 2025 Dec 1;11(12):1542-1545. doi: 10.1001/jamaoncol.2025.4349.

Eric Milan Mukherjee^{1

2}, Dodie Park², Amir Asiaee³, Matthew S Krantz^{2

4}, Cosby A Stone Jr^{2

4}, Michelle Martin-Pozo^{2

4}, Elizabeth Phillips^{2

4

5}

¹ Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.
² Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
³ Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
⁴ Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee.
⁵ Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Australia.

No abstract available

Plain language summary

This cross-sectional study examines the association of immune checkpoint inhibitor use with Stevens-Johnson syndrome, toxic epidermal necrolysis.